TH9507 · 10 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
Tesamorelin 10 mg
Approved GHRH analogue — stabilised long-acting GRF(1-44).
Tesamorelin is an approved GHRH analogue. The research-grade form is used widely in GH-axis, lipid-metabolism, and hepatic-fat research.
What the peptide is.
Tesamorelin (TH9507) is a stabilised 44-residue analogue of human GHRH, developed by Theratechnologies. The trans-3-hexenoyl N-terminal modification confers enzymatic stability.
FDA approved in 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy. More recent clinical research has examined effects on NAFLD (non-alcoholic fatty liver disease).
Agonism at the GHRH receptor → pituitary GH release → IGF-1 elevation. Mass-balance effects on visceral adipose tissue documented in HIV-lipodystrophy RCTs.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Standard peptide handling.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT Tesamorelin 10 mg
DESIGNATION TH9507
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.00
MASS EXP. 5196.00 Da
MASS OBS. 5196.02 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for Tesamorelin 10 mg.
2 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Falutz J, Allas S, Blot K, et al.
Metabolic effects of a growth hormone-releasing factor in patients with HIV
New England Journal of Medicine · 2007 - [02]Stanley TL, Feldpausch MN, Oh J, et al.
Effect of Tesamorelin on Visceral Fat and Liver Fat
JCEM · 2014
- Q.How is this different from sermorelin?
- A.Sermorelin is GRF(1-29) — a shorter fragment of GHRH. Tesamorelin is GRF(1-44) with a trans-3-hexenoyl N-terminal modification for enzymatic stability. Tesamorelin reached approval; sermorelin was withdrawn.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
Sermorelin 10 mg
GHRH(1-29) analogue — the minimum fragment with full GH-releasing activity.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
CJC-1295 with DAC 5 mg
Long-acting GHRH analogue with Drug Affinity Complex.
- Form
- Lyophilised kit
- Dose
- 5 mg / vial
- Purity
- ≥ 99.0%
IGF-1 LR3 1 mg
Modified IGF-1 — reduced IGFBP binding, ~83-residue analogue.
- Form
- Lyophilised kit
- Dose
- 1 mg / vial
- Purity
- ≥ 98.0%